RecruitingNot ApplicableNCT06512545

Modified Second Haplo-transplantation for Graft Failure

Second Haploidentical Transplantation with Modified Regimen for Graft Failure After the First Allogeneic Stem Cell Transplantation

Sponsor

Peking University People's Hospital

Enrollment

12 participants

Start Date

Jul 1, 2024

Study Type

INTERVENTIONAL

Conditions

Stem Cell Transplant Complications Graft Failure

Summary

Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. We previously reported encouraging results with a novel Flu/Cy regimen. However, there are still around 20% patients developed delayed platelet recovery. We designed a modified regimen to further improve the hematopoietic reconstitution after second transplantation. This prospective, single-arm study aims to investigate the safety and efficacy of this modified regimen.

Eligibility

Min Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying second allogeneic stem cell transplantation for people with graft failure and stem cell transplant complications. The study is currently recruiting participants at 1 location. People eligible for this study include aged 14 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERsecond allogeneic stem cell transplantation

1. Change another donor if possible 2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 )/cyclophosphamide (1g/m2/day, days -5 to -4)/rabbit antithymocyte globulin (1.5mg/kg/day, days -4 to -2) 3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg, +1d, +8d, +15d)